SCHEMBL9607597

SCHEMBL9607597

CN(C)C(=O)C(C)(C)CO

nearest known ligand 0.38

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.32
TSHR P16473 1/20 0.32
RIPK1 Q13546 1/20 0.31
DRD4 P21917 1/20 0.31
OPRM1 P35372 1/20 0.31
DRD3 P35462 1/20 0.31
MAPT P10636 1/20 0.30
MEN1 O00255 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2C9 P11712 1/20 0.30
CYP2C19 P33261 1/20 0.30
KMT2A Q03164 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8880685 0.78 ALDH1A1 (0.32) ALDH1A1TSHRRIPK1DRD4OPRM1
SCHEMBL2740778 0.78 RIPK1 (0.47) RIPK1
SCHEMBL19608819 0.77 RIPK1 (0.39) RIPK1
SCHEMBL11621506 0.76 ALDH1A1 (0.36) ALDH1A1TSHRDRD4OPRM1DRD3
SCHEMBL5264333 0.76 ALDH1A1 (0.40) ALDH1A1TSHRRIPK1DRD4OPRM1
SCHEMBL20857549 0.76 ALDH1A1 (0.30) ALDH1A1TSHR
SCHEMBL12293705 0.76 ALDH1A1 (0.30) ALDH1A1TSHRCYP3A4CYP2C9CYP2C19
SCHEMBL11809225 0.76 KDM4E (0.36) ALDH1A1TSHR
SCHEMBL23370118 0.75 AOC2 (0.35)
SCHEMBL1712705 0.75 MAPT (0.42) RIPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed
WO-2023230543-A1 INDOLIZINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed
WO-2023230542-A2 PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed
EP-2462104-B1 METHOD FOR SYNTHESIZING AMINOALCOHOLS LUBRIZOL ADVANCED MAT INC (US) 2016-11-23 EP disclosed
US-8766011-B2 Method for synthesizing aminoalcohols LUBRIZOL ADVANCED MATERIALS, INC. (US) 2014-07-01 US disclosed
US-20120136174-A1 Method For Synthesizing Aminoalcohols LUBRIZOL ADVANCED MATERIALS, INC. (US) 2012-05-31 US disclosed
WO-2011017510-A2 METHOD FOR SYNTHESIZING AMINOALCOHOLS LUBRIZOL ADVANCED MATERIALS, INC. (US) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136174-A1 Method For Synthesizing Aminoalcohols THEM6, AADAT, INF2 ALDH1A1 366/4885TSHR 4696/4885RIPK1 1987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.